John Shannon is the Chief Executive Officer of Xeris Biopharma Holdings Inc., a specialty pharmaceutical company focused on developing and commercializing innovative treatments for patients with endocrine and metabolic disorders. With over three decades of experience in the pharmaceutical industry, Shannon has built a reputation for driving growth and innovation in various leadership roles. Before joining Xeris Biopharma, Shannon served as the President and CEO of Allergan, where he played a pivotal role in transforming the company into a global leader in medical aesthetics and specialty pharmaceuticals. Under his leadership, Allergan achieved significant milestones, including the successful launch of several blockbuster products and the expansion of its global footprint. Prior to Allergan, Shannon held senior executive positions at major pharmaceutical companies such as Eli Lilly and Company and GlaxoSmithKline, where he demonstrated his ability to lead high-performing teams and deliver strong financial results. As CEO of Xeris Biopharma, John Shannon is responsible for overseeing the company's strategic direction, operational execution, and growth initiatives. He has been instrumental in advancing Xeris' pipeline of novel therapies, including the development of ready-to-use liquid stable formulations of glucagon for the treatment of severe hypoglycemia. Shannon's leadership has been crucial in positioning Xeris Biopharma as a key player in the endocrine and metabolic disorder market, with a focus on improving patient outcomes and driving shareholder value.